Deutsche Bank’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

Deutsche Bank’s Portfolio BIOT Stock Details BIOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-250,000	Closed	-$2.52M	–	4067
2022 Q4	$2.52M	Hold	250,000	–	–	﹤0.01%	1524
2022 Q3	$2.48M	Hold	250,000	–	–	﹤0.01%	1515
2022 Q2	$2.48M	Hold	250,000	–	–	﹤0.01%	1647
2022 Q1	$2.46M	Hold	250,000	–	–	﹤0.01%	1768
2021 Q4	$2.46M	Hold	250,000	–	–	﹤0.01%	1862
2021 Q3	$2.44M	Hold	250,000	–	–	﹤0.01%	1953
2021 Q2	$2.42M	Buy	+250,000	New	+$2.43M	﹤0.01%	2061

Deutsche Bank's BIOT Position: Q1 2023 in Review

Deutsche Bank sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q1 2023, closing a stake of 250,000 shares — an estimated $2.52M sold.

Deutsche Bank first reported a position in BIOT in Q2 2021 and held it in 7 quarters. The position peaked at $2.52M in Q4 2022. 0 funds tracked by Wall St. Rank hold BIOT as of Q1 2023.

Deutsche Bank reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Deutsche Bank sold 250,000 Biotech Acquisition Company Class A Ordinary Shares shares in Q1 2023, an estimated $2.52M.
Deutsche Bank first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q2 2021 and held it in 7 quarters.
Deutsche Bank's Biotech Acquisition Company Class A Ordinary Shares position peaked at $2.52M in Q4 2022.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q1 2023.

Based on Deutsche Bank's 13F filing for Q1 2023, filed 15 May 2023.